R&D channel feed – Endpoints News

R&D channel feed

Small Nebraska startup hopes to challenge Pfizer, Merck in pneumococcal vaccine race

3 years ago

Inovio’s decades of shifting extends to wayward winter in pipeline, workforce thinning

3 years ago

New York City invests $20M into biotech 'innovation space' at the Brooklyn Navy Yard

3 years ago

Boehringer Ingelheim touts prevention results in rarest form of psoriasis

3 years ago

‘The field is at a flashpoint’: New Chad Mirkin-founded biotech hopes to make more effective cancer vaccines

3 years ago

CureVac touts older adult data for GSK-partnered Covid-19, flu candidates

3 years ago

Lilly enters ripe BTK field with quick FDA nod in mantle cell lymphoma

3 years ago

Novartis' approved sickle cell disease drug fails to beat placebo in PhIII

3 years ago

FDA approves another indication for Keytruda, this time in the adjuvant NSCLC setting

3 years ago

J&J, Legend say Carvykti beat standard therapy in earlier-line blood cancer

3 years ago

Dutch biotech starts liquidation after ending PhIII in GVHD

3 years ago

Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia

3 years ago

Aridis' monoclonal antibody fails PhIII, but plans for second trial anyway

3 years ago

XyloCor wraps up PhII for heart disease gene therapy, plans for pivotal trial

3 years ago

Oral drug for diabetic retinopathy flunks PhII, but biotech wants to go into PhIII with new endpoint

3 years ago

Patient death spurs trial halt for Magenta Therapeutics

3 years ago

Merck halts prostate cancer study while reporting positive readout in biliary tract cancer

3 years ago

FDA adcomm votes in favor of new antifungal; Denali gets $25M from Sanofi MS trial milestone

3 years ago

J&J quietly punts a pair of early-stage bispecifics for solid tumors

3 years ago

Construction on Merck's London research hub set to begin in April 2023

3 years ago

Axcella seeks 'light speed' swing at long Covid, but needs cash

3 years ago

CymaBay looks to raise $85M as liver drug's PhIII readout looms

3 years ago

Crushed by PhIII antibiotic flop, PolyPid says it got FDA support for a comeback — by focusing on subgroup

3 years ago

Finch throws in the towel on microbiome journey, lets go of 77 employees

3 years ago

First page Previous page 101 102 103104105 106 107 Next page Last page